Douglas McQuaid, MD
Pulmonary Disease · High Point, NCNPI 1124230776
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,043 and has fallen 98.7% since, to $14 in 2025.
Across 130 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$371
- Boehringer Ingelheim$284
- AstraZeneca$279
- Inari Medical, Inc.$234
- Sanofi$178
- Merck$157
- plus $870 from 23 others
Across 2 payments — averaging $840.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
- Merck$61
What the payments were for
- Food & beverage$2,34699%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $371 |
| Boehringer Ingelheim | 16 | $284 |
| AstraZeneca | 12 | $279 |
| Inari Medical, Inc. | 1 | $234 |
| Sanofi | 3 | $178 |
| Merck | 11 | $157 |
| Actelion Pharmaceuticals US, Inc. | 7 | $119 |
| Philips North America LLC | 6 | $108 |
| Novartis | 8 | $106 |
| Inogen, Inc. | 7 | $64 |
| Mylan Specialty L.p. | 4 | $58 |
| Genentech USA, Inc. | 4 | $58 |
| Grifols USA, LLC | 2 | $39 |
| United Therapeutics Corporation | 2 | $38 |
| Insmed, Inc. | 2 | $29 |
| Gilead | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Electromed, Inc. | 2 | $23 |
| Baxter Healthcare | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Amgen | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| Quidel Corporation | 1 | $12 |
| Teleflex LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$467
- DUPIXENT$150
- ANDEXXA$124
How this compares
$2,372 in reported general payments places this provider in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $62,925 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $30,317 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $23,911 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,391 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,547 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,423 |
| EliquisApixaban | 12 | $7,123 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,909 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,526 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $1,859 |
| Fluticasone Propionate | 16 | $174 |
| Losartan Potassium | 16 | $155 |
| Prednisone | 60 | $113 |
| Doxycycline Hyclate | 19 | $110 |
| Furosemide | 19 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $371 | $85,388149 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $284 | $32,33460 claims |
| AstraZenecaBreztri Aerosphere | $279 | $30,31745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in High Point
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.